Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Breast 1

Conditions

Ovarian Neoplasms 12Fallopian Tube Neoplasms 6Breast Neoplasms 6Endometrial Neoplasms 4Prostatic Neoplasms 3Pancreatic Neoplasms 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Carcinoma, Ovarian Epithelial 2Carcinoma, Non-Small-Cell Lung 2Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Ewing 1Recurrence 1Neoplasm Metastasis 1Mesothelioma 1Fanconi Anemia, Complementation Group D1 1Colorectal Neoplasms 1Advanced Ovarian Cancer 1

Interventions

Carboplatin 19Paclitaxel 17Cisplatin 9Cyclophosphamide 8Gemcitabine 7Bevacizumab 6Topotecan 5pembrolizumab 4olaparib 4liposomal doxorubicin 4durvalumab 4Letrozole 4Interleukin-2 4Drug Therapy 4Doxorubicin 4Albumin-Bound Paclitaxel 4rucaparib 3fludarabine 3chiauranib 3cemiplimab 3camrelizumab 3Therapeutics 3Itraconazole 3Injections 3Hyperthermic Intraperitoneal Chemotherapy 3Everolimus 3pazopanib 2iniparib 2eprenetapopt 2avelumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × talazoparib × Gynecologic × Clear all
NCT03330405 2023-10-13

Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

Pfizer

Phase 1/2 Terminated
223 enrolled 50 charts
BreastGynecologicThoracic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡